Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori
Advertisement

Related Content

Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
Will Ranbaxy Tie Up With Teva To Launch Generic Lipitor?
Dr. Reddy's Labs Saved From Poor India Showing By North America Market Growth, Biosimilars
Dr. Reddy's Labs Saved From Poor India Showing By North America Market Growth, Biosimilars
Teva Buys Japanese Generics Company For $460 Mil.
Fujifilm Acquires Two Merck Bio Units Looking To Ramp Up Pharma Business
India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy
Fujifilm Focuses On Future Of Generics In Japan
Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs
Advertisement
UsernamePublicRestriction

Register

SC078614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel